Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Canadian Pharma Co. Advances Chronic Cough Study

Stockhouse Editorial
1 Comment| February 4, 2022

{{labelSign}}  Favorites
{{errorMessage}}

Click to enlargeClinical stage pharmaceutical development company Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: BTHCF, Forum) reported on Friday that it had completed enrollment in its Phase 2 NP-120 idiopathic pulmonary fibrosis (IPF) and chronic cough study.

This human trial is to determine the efficacy of Ifenprodil in the preservation of lung function in IPF patients (including biomarkers of fibrosis) and its associated cough.

The company’s CEO, Christopher J. Moreau said in a news release – “We are very pleased to announce this update to the market on our IPF and chronic cough study and we look forward to having it completed and presenting the data.”

To read more about this study, click here.

There are seven sites in total participating in the study with five located in Australia and two in New Zealand. The company is projecting a data readout in calendar Q2, 2022.

The drug re-purposing company made news recently when received a notice of allowance for Ifenprodil patent application for IPF in late January 2022.

For more on this company, visit algernonpharmaceuticals.com.


To learn about some of the most-talked about Healthcare stocks on Stockhouse, check out the Healthcare Bullboards.

For more of the latest info on Healthcare stocks, check out the Healthcare Trending News hub on Stockhouse.


FULL DISCLOSURE: Algernon Pharmaceuticals Inc. is a client of Stockhouse Publishing.




{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today